このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Merck マネジメント

マネジメント基準チェック /34

Merck'sの CEO はRob Davisで、 Apr2021年に任命され、の在任期間は 3.17年です。の年間総報酬は$ 20.27Mで、 7.9%給与と92.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.014%を直接所有しており、その価値は$ 44.40M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と4.8年です。

主要情報

Rob Davis

最高経営責任者

US$20.3m

報酬総額

CEO給与比率	7.9%
CEO在任期間	3.4yrs
CEOの所有権	0.01%
経営陣の平均在職期間	3.7yrs
取締役会の平均在任期間	5yrs

経営陣の近況

Recent updates

CEO報酬分析

Merck の収益と比較して、Rob Davis の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

報酬と市場: Robの総報酬 ($USD 20.27M ) は、 PE市場 ($USD 5.85M ) の同規模の企業の平均を上回っています。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Rob Davis (57 yo)

3.4yrs

在職期間

US$20,273,287

報酬

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	3.4yrs	US$20.27m	0.014% $ 40.0m
Caroline Litchfield	Executive VP & CFO	3.4yrs	US$8.30m	0.0020% $ 5.8m
Richard DeLuca	Executive VP & President of Merck Animal Health	13yrs	US$6.20m	0.0060% $ 17.4m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	14.8yrs	US$6.24m	0.0062% $ 18.0m
Dean Li	Executive VP & President of Merck Research Laboratories	6.8yrs	US$9.78m	0.0018% $ 5.3m
Dalton Smart	Senior VP of Finance	less than a year	データなし	0.00017% $ 494.4k
David Williams	Executive VP and Chief Information & Digital Officer	no data	データなし	0.00078% $ 2.3m
Peter Dannenbaum	Vice President of Investor Relations	5.1yrs	データなし	データなし
Jennifer Zachary	Executive VP & General Counsel	6.4yrs	US$5.90m	0.0011% $ 3.3m
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	3.1yrs	データなし	データなし
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	データなし	データなし
Johannes Oosthuizen	Senior VP & President Merck U.S. Human Health	3.7yrs	データなし	0.00094% $ 2.7m

3.7yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: MRKの経営陣は経験豊富であると考えられます ( 3.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	3.2yrs	US$20.27m	0.014% $ 40.0m
Pamela Craig	Independent Director	9yrs	US$400.00k	0.000070% $ 203.6k
Patricia Russo	Independent Director	29yrs	US$360.00k	0.00052% $ 1.5m
Thomas Glocer	Independent Lead Director	16.8yrs	US$430.10k	0.00020% $ 581.6k
Risa Lavizzo-Mourey	Independent Director	4.3yrs	US$365.00k	0.000040% $ 116.3k
Douglas Baker	Independent Director	2.3yrs	US$347.64k	0.000040% $ 116.3k
Inge Thulin	Independent Director	6.5yrs	US$340.00k	0% $ 0
Stephen Mayo	Independent Director	3.5yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	4.5yrs	US$350.00k	0.000020% $ 58.2k
Christine Seidman	Independent Director	4.5yrs	US$350.00k	0% $ 0
Paul Rothman	Independent Director	9yrs	US$380.00k	0% $ 0
Mary Coe	Independent Director	5.5yrs	US$342.36k	0% $ 0

5.0yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: MRKの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Merck マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

Recent updates

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

New minor risk - Share price stability

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$2.14 (vs US$2.35 loss in 2Q 2023)

First quarter dividend of US$0.77 announced

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension (PAH)

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma

Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34